Javascript must be enabled to continue!
MIRTAZAPINE LOADED PRONANOMICELLES: PREPARATION AND CHARACTERIZATION
View through CrossRef
Objective: The aim of this work was to prepare mirtazapine-loaded self-assembled micelles using soluplus®, solutol®HS15 and TPGs to enhance mirtazapine solubility and thus oral bioavailability.
Methods: MTZ nanomicelles were produced by the thin-film hydration method using different polymers in different ratios to prepare stable MTZ nanomicelles, where the soluplus® nanomicelles formula in different ratios was F1 to F4; soluplus® in combination with TPGS to stabilize the nanomicelles formula was formulated in different ratios as in F5 to F10; and soluplus® in combination with SolutolHS 15 as in F10 to F14. The most stable formula is further investigated with particle size, polydispersity index, drug loading, entrapment efficacy, and in vitro release, and then the selected formula is statistically further investigated with FTIR, DSC, and FESEM.
Results: The particle size of the prepared formula ranged from 57 nm for F4 (1:10 of MTZ: soluplus®) to 78 nm for F8 (1:8:4 of MTZ: soluplus®: TPGS); the EE% ranged from 85% to 90%; FTIR analysis suggested no chemical interaction; FESEM showed spherical nanomicelles in Nano size; and DSC showed the transition of the drug to an amorphous form due to MTZ entrapment with in nanomicelles.
Conclusion: Mirtazapine-loaded Soluplus® micelles alone and in combination, first with TPGS and second with Solutol HS 15 by the thin-film hydration method show uniform distribution of particle size, PDI, and enhancement in the in vitro release of the drug.
Innovare Academic Sciences Pvt Ltd
Title: MIRTAZAPINE LOADED PRONANOMICELLES: PREPARATION AND CHARACTERIZATION
Description:
Objective: The aim of this work was to prepare mirtazapine-loaded self-assembled micelles using soluplus®, solutol®HS15 and TPGs to enhance mirtazapine solubility and thus oral bioavailability.
Methods: MTZ nanomicelles were produced by the thin-film hydration method using different polymers in different ratios to prepare stable MTZ nanomicelles, where the soluplus® nanomicelles formula in different ratios was F1 to F4; soluplus® in combination with TPGS to stabilize the nanomicelles formula was formulated in different ratios as in F5 to F10; and soluplus® in combination with SolutolHS 15 as in F10 to F14.
The most stable formula is further investigated with particle size, polydispersity index, drug loading, entrapment efficacy, and in vitro release, and then the selected formula is statistically further investigated with FTIR, DSC, and FESEM.
Results: The particle size of the prepared formula ranged from 57 nm for F4 (1:10 of MTZ: soluplus®) to 78 nm for F8 (1:8:4 of MTZ: soluplus®: TPGS); the EE% ranged from 85% to 90%; FTIR analysis suggested no chemical interaction; FESEM showed spherical nanomicelles in Nano size; and DSC showed the transition of the drug to an amorphous form due to MTZ entrapment with in nanomicelles.
Conclusion: Mirtazapine-loaded Soluplus® micelles alone and in combination, first with TPGS and second with Solutol HS 15 by the thin-film hydration method show uniform distribution of particle size, PDI, and enhancement in the in vitro release of the drug.
Related Results
The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder
The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder
Introduction
Mirtazapine is commonly prescribed to patients diagnosed with major depressive disorder.Some proportion of these patients do not show adequate response to treatment re...
Impact of the Omics-Based Biomarkers on the Mirtazapine’s Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
Impact of the Omics-Based Biomarkers on the Mirtazapine’s Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
Introduction:
Mirtazapine is commonly administered to patients with recurrent depressive disorder. Some of these patients do not show adequate response to the therapy with mirtazap...
1388 Ultra-Low Dose Mirtazapine (3.75 Mg) for Insomnia: Efficacy and Residual Sedation
1388 Ultra-Low Dose Mirtazapine (3.75 Mg) for Insomnia: Efficacy and Residual Sedation
Abstract
Introduction
Mirtazapine has complex pharmacologic properties, with lower doses exerting sedative effects throug...
Fabrication of Hydroxypropyl Methylcellulose Orodispersible Film Loaded Mirtazapine Using a Syringe Extrusion 3D Printer
Fabrication of Hydroxypropyl Methylcellulose Orodispersible Film Loaded Mirtazapine Using a Syringe Extrusion 3D Printer
Depression is a mental illness causing a continuous negative feeling and loss of interest and affects physical and mental health. Mirtazapine (MTZ) is an effective medicine for tre...
Mirtazapine in veterinary medicine: focus on its role in gastrointestinal disorders - review
Mirtazapine in veterinary medicine: focus on its role in gastrointestinal disorders - review
Mirtazapine, a tetracyclic antidepressant, has gained attention in recent years for its potential applications in veterinary medicine. This review article aims to comprehensively e...
The influence of concentration of micro-rna hsa-mir-370-3p and CYP2D6*4 on equilibrium concentration of mirtazapine in patients with major depressive disorder
The influence of concentration of micro-rna hsa-mir-370-3p and CYP2D6*4 on equilibrium concentration of mirtazapine in patients with major depressive disorder
IntroductionMirtazapine is commonly prescribed to patients diagnosed with major depressive disorder.Some proportion of these patients do not show adequate response to treatment reg...
First report of mirtazapine-induced arthralgia
First report of mirtazapine-induced arthralgia
SummaryObjective.The aim of our work is to describe the first two cases of arthralgia associated with the antidepressant drug mirtazapine.Method.Descriptive analysis of two iatroge...
Mirtazapine for the Treatment of Chronic Pruritus
Mirtazapine for the Treatment of Chronic Pruritus
Background: Chronic pruritus is a debilitating condition associated with a wide range of dermatologic, systemic and psychogenic etiologies. In patients with chronic pruritus that i...

